Selection of nanobodies with broad neutralizing potential against primary HIV-1 strains using soluble subtype C gp140 envelope trimers
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Selection of nanobodies with broad neutralizing potential against primary HIV-1 strains using soluble subtype C gp140 envelope trimers ; volume:7 ; number:1 ; day:21 ; month:8 ; year:2017 ; pages:1-15 ; date:12.2017
Scientific reports ; 7, Heft 1 (21.8.2017), 1-15, 12.2017
- Urheber
-
Koch, Kathrin
Kalusche, Sarah
Torres, Jonathan L.
Stanfield, Robyn L.
Danquah, Welbeck
Khazanehdari, Kamal
Briesen, Hagen von
Geertsma, Eric R.
Wilson, Ian A.
Wernery, Ulrich
Koch-Nolte, Friedrich
Ward, Andrew B.
Dietrich, Ursula
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-017-08273-7
- URN
-
urn:nbn:de:101:1-2019102014540918995458
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:36 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Koch, Kathrin
- Kalusche, Sarah
- Torres, Jonathan L.
- Stanfield, Robyn L.
- Danquah, Welbeck
- Khazanehdari, Kamal
- Briesen, Hagen von
- Geertsma, Eric R.
- Wilson, Ian A.
- Wernery, Ulrich
- Koch-Nolte, Friedrich
- Ward, Andrew B.
- Dietrich, Ursula
- SpringerLink (Online service)
Ähnliche Objekte (12)
NeutrobodyPlex—monitoring SARS‐CoV‐2 neutralizing immune responses using nanobodies
Broad‐Spectrum Engineered Multivalent Nanobodies Against SARS‐CoV‐1/2
Neutralizing antibodies targeting a novel epitope on envelope protein exhibited broad protection against flavivirus without risk of disease enhancement
Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability
Differences in neutralizing antibody sensitivities and envelope characteristics indicate distinct antigenic properties of Nigerian HIV-1 subtype G and CRF02_AG
Stabilizing HIV-1 envelope glycoprotein trimers to induce neutralizing antibodies
![Development of broadly neutralizing nanobodies (VHHs) against primary HIV-1 towards prophylastic applications, [Band].](/assets/placeholder/searchResultMediaNoDigitisedMedia.png)
Development of broadly neutralizing nanobodies (VHHs) against primary HIV-1 towards prophylastic applications, [Band].
Lactobacilli expressing broadly neutralizing nanobodies against HIV-1 as potential vectors for HIV-1 prophylaxis?
P09-12. Autologous neutralizing antibodies in early subtype C HIV-1 infection target variable regions of envelope and drive multiple pathways of viral escape
HIV-1 envelope trimer elicits higher neutralizing antibody responses than monomeric gp120
Development of Neutralizing Antibodies against Zika Virus Based on Its Envelope Protein Structure
Neutralizing and non-neutralizing antibody responses in HIV-1 subtype C chronically infected patients with divergent rates of disease progression
NeutrobodyPlex—monitoring SARS‐CoV‐2 neutralizing immune responses using nanobodies
Broad‐Spectrum Engineered Multivalent Nanobodies Against SARS‐CoV‐1/2
Neutralizing antibodies targeting a novel epitope on envelope protein exhibited broad protection against flavivirus without risk of disease enhancement
Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability
Differences in neutralizing antibody sensitivities and envelope characteristics indicate distinct antigenic properties of Nigerian HIV-1 subtype G and CRF02_AG
Stabilizing HIV-1 envelope glycoprotein trimers to induce neutralizing antibodies
Development of broadly neutralizing nanobodies (VHHs) against primary HIV-1 towards prophylastic applications, [Band].
Lactobacilli expressing broadly neutralizing nanobodies against HIV-1 as potential vectors for HIV-1 prophylaxis?
P09-12. Autologous neutralizing antibodies in early subtype C HIV-1 infection target variable regions of envelope and drive multiple pathways of viral escape
HIV-1 envelope trimer elicits higher neutralizing antibody responses than monomeric gp120
Development of Neutralizing Antibodies against Zika Virus Based on Its Envelope Protein Structure
Neutralizing and non-neutralizing antibody responses in HIV-1 subtype C chronically infected patients with divergent rates of disease progression
NeutrobodyPlex—monitoring SARS‐CoV‐2 neutralizing immune responses using nanobodies
Broad‐Spectrum Engineered Multivalent Nanobodies Against SARS‐CoV‐1/2
Neutralizing antibodies targeting a novel epitope on envelope protein exhibited broad protection against flavivirus without risk of disease enhancement
Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability
Differences in neutralizing antibody sensitivities and envelope characteristics indicate distinct antigenic properties of Nigerian HIV-1 subtype G and CRF02_AG
Stabilizing HIV-1 envelope glycoprotein trimers to induce neutralizing antibodies
Development of broadly neutralizing nanobodies (VHHs) against primary HIV-1 towards prophylastic applications, [Band].
Lactobacilli expressing broadly neutralizing nanobodies against HIV-1 as potential vectors for HIV-1 prophylaxis?
P09-12. Autologous neutralizing antibodies in early subtype C HIV-1 infection target variable regions of envelope and drive multiple pathways of viral escape
HIV-1 envelope trimer elicits higher neutralizing antibody responses than monomeric gp120
Development of Neutralizing Antibodies against Zika Virus Based on Its Envelope Protein Structure